ClinicalTrials.gg
CompletedNCT04556656Updated Mar 12, 2025Results posted

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

A Phase 3 interventional study of Pridopidine and Placebo in Huntington Disease, sponsored by Prilenia. Completed at 58 sites in 11 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Prilenia · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
499
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
5th of 90
499 · median 44
Started
2020
with 7 others
Phase 3
14 of 138
2 open now
Registered
101st of 138
by date
Lead sponsor
4 of 138
Prilenia

Among the 138 studies in Huntington Disease with a site in United States, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2020, is one of 14 in phase 3, and was the 101st registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).

Read the detailed description

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine 45 mg BID in patients with early stage HD.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • Huntington Disease
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of HD based on clinical features and the presence of ≥36 CAG repeats in the huntingtin gene
  2. Diagnostic confidence level (DCL) of 4
  3. Adult-onset HD with onset of signs and symptoms ≥18 years of age
  4. Stage 1 or Stage 2 HD, defined as a UHDRS-TFC score of ≥7, at screening

Exclusion criteria

EXCLUSION CRITERIA

  1. Use of pridopidine within 12 months before the baseline visit.
  2. Gene therapy at any time
  3. Any serious medical condition or laboratory, or vital sign abnormality that precludes the patient's safe participation in and completion of the study e.g. significant heart disease within 12 weeks before baseline or history of certain cardiac arrhythmias
  4. History of epilepsy or seizures within the last 5 years
  5. Pregnant or breastfeeding, or intention to become pregnant during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
499 participants (actual)

Study arms

  • Experimental
    Pridopidine

    45 mg pridopidine twice daily (BID)

    Drug: Pridopidine

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Pridopidine hard gelatin capsule

  • DrugPlacebo

    Pridopidine-matching placebo hard gelatin capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)

    The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.

    Time frame: From baseline to Week 65

  2. Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)

    The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.

    Time frame: From baseline to Week 65.

Secondary outcomes

  1. Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT)

    The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components: Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0. Total integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better.

    Time frame: From baseline to Week 65

Other outcomes

  1. Change From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT)

    The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details): Total Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better. Total cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better. This sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78

  2. Change From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT)

    Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 52, Week 65, and Week 78.

  3. Change From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT)

    Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 52, Week 65, and Week 78.

  4. Change in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT)

    Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 52, Week 65, and Week 78.

  5. Change From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT)

    Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78

  6. Change From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT)

    Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78

  7. Change From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT)

    Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78.

  8. Change From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT)

    Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

    Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78.

07

Results

Posted Mar 12, 2025

Participant flow

Participant flow — Overall Study
MilestonePridopidinePlacebo
Started250249
Completed222227
Not completed2822
Withdrew: Withdrawal by subject1412
Withdrew: Physician decision10
Withdrew: Adverse event47
Withdrew: Death40
Withdrew: Lost to follow-up32
Withdrew: Not further specified21

Outcome measures

PrimaryChange From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)

The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.

Time frame:
From baseline to Week 65
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)
score on a scalePridopidinePlacebo
Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)-1.18 ± 0.119-0.95 ± 0.119
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1670 · Mean difference (final values): -0.22 · 95% CI -0.54 to 0.09
PrimaryChange From Baseline to Week 65 in the UHDRS TFC Score (ITT)

The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.

Time frame:
From baseline to Week 65.
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)
score on a scalePridopidinePlacebo
Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)-1.17 ± 0.120-0.94 ± 0.120
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1598 · Mean difference (final values): -0.23 · 95% CI -0.55 to 0.09
SecondaryChange From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT)

The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components: Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0. Total integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better.

Time frame:
From baseline to Week 65
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT)
score on a scalePridopidinePlacebo
Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT)-0.99 ± 0.109-0.88 ± 0.108
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.4544 · Mean difference (final values): -0.11 · 95% CI -0.4 to 0.18
Other pre-specifiedChange From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT)

The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details): Total Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better. Total cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better. This sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78
Reported as:
Least squares mean · score on a scale
Change From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT)
score on a scalePridopidinePlacebo
Week 260.15 ± 0.114-0.31 ± 0.108
Week 390.10 ± 0.130-0.34 ± 0.125
Week 52-0.07 ± 0.140-0.48 ± 0.135
Week 65-0.26 ± 0.143-0.53 ± 0.137
Week 78-0.40 ± 0.159-0.54 ± 0.158
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0038 · Mean difference (final values): 0.46 · 95% CI 0.15 to 0.76
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0135 · Mean difference (final values): 0.45 · 95% CI 0.09 to 0.80
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0351 · Mean difference (final values): 0.41 · 95% CI 0.03 to 0.79
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1683 · Mean difference (final values): 0.27 · 95% CI -0.12 to 0.66
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.5315 · Mean difference (final values): 0.14 · 95% CI -0.30 to 0.58
Other pre-specifiedChange From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT)

Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 52, Week 65, and Week 78.
Reported as:
Least squares mean · milliseconds (decrease = improvement)
Change From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT)
milliseconds (decrease = improvement)PridopidinePlacebo
Week 26-14.85 ± 6.8466.30 ± 6.449
Week 52-2.37 ± 7.13511.95 ± 6.792
Week 65-0.79 ± 7.36523.93 ± 7.028
Week 781.46 ± 7.44424.36 ± 7.230
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0253 · Mean difference (final values): -21.15 · 95% CI -39.66 to -2.64Negative change = improvement.
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1474 · Mean difference (final values): -14.31 · 95% CI -33.71 to 5.08
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0159 · Mean difference (final values): -24.71 · 95% CI -44.76 to -4.67
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0283 · Mean difference (final values): -22.90 · 95% CI -43.34 to -2.45
Other pre-specifiedChange From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT)

Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 52, Week 65, and Week 78.
Reported as:
Least squares mean · milliseconds
Change From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT)
millisecondsPridopidinePlacebo
Week 26-17.63 ± 8.02920.43 ± 7.448
Week 52-0.15 ± 9.12420.07 ± 8.555
Week 654.64 ± 8.38028.55 ± 7.867
Week 7812.73 ± 9.74034.97 ± 9.412
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0007 · Mean difference (final values): -38.06 · 95% CI -59.74 to -16.37
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1087 · Mean difference (final values): -20.21 · 95% CI -44.95 to 4.53
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0395 · Mean difference (final values): -23.92 · 95% CI -46.68 to -1.16
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1038 · Mean difference (final values): -22.23 · 95% CI -49.08 to 4.61
Other pre-specifiedChange in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT)

Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 52, Week 65, and Week 78.
Reported as:
Least squares mean · milliseconds
Change in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT)
millisecondsPridopidinePlacebo
Week 26-16.70 ± 9.39913.68 ± 8.829
Week 527.40 ± 10.97824.23 ± 10.467
Week 657.34 ± 10.73030.13 ± 10.232
Week 7819.21 ± 12.70241.93 ± 12.435
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0193 · Mean difference (final values): -30.38 · 95% CI -55.78 to -4.98
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2680 · Mean difference (final values): -16.84 · 95% CI -46.69 to 13.02
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1255 · Mean difference (final values): -22.79 · 95% CI -51.97 to 6.4
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2024 · Mean difference (final values): -22.72 · 95% CI -57.72 to 12.28
Other pre-specifiedChange From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT)

Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78
Reported as:
Least squares mean · score on a scale
Change From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT)
score on a scalePridopidinePlacebo
Week 26-0.01 ± 0.131-0.23 ± 0.124
Week 39-0.11 ± 0.137-0.31 ± 0.131
Week 52-0.19 ± 0.149-0.45 ± 0.143
Week 65-0.49 ± 0.156-0.54 ± 0.150
Week 78-0.42 ± 0.166-0.54 ± 0.163
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2088 · Mean difference (final values): 0.22 · 95% CI -0.13 to 0.58
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2991 · Mean difference (final values): 0.20 · 95% CI -0.17 to 0.57
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2116 · Mean difference (final values): 0.26 · 95% CI -0.15 to 0.66
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.8242 · Mean difference (final values): 0.05 · 95% CI -0.38 to 0.47
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.5918 · Mean difference (final values): 0.12 · 95% CI -0.33 to 0.58
Other pre-specifiedChange From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT)

Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78
Reported as:
Least squares mean · score on a scale
Change From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT)
score on a scalePridopidinePlacebo
Week 262.34 ± 0.964-0.82 ± 0.916
Week 392.85 ± 1.100-0.04 ± 1.051
Week 522.73 ± 1.078-0.32 ± 1.039
Week 651.39 ± 1.243-0.94 ± 1.193
Week 780.91 ± 1.261-1.08 ± 1.249
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0178 · Mean difference (final values): 3.16 · 95% CI 0.55 to 5.77
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0576 · Mean difference (final values): 2.89 · 95% CI -0.09 to 5.88
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.0418 · Mean difference (final values): 3.05 · 95% CI 0.11 to 5.99
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1775 · Mean difference (final values): 2.32 · 95% CI -1.06 to 5.71
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2627 · Mean difference (final values): 1.99 · 95% CI -1.50 to 5.48
Other pre-specifiedChange From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT)

Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78.
Reported as:
Least squares mean · score on a scale
Change From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT)
score on a scalePridopidinePlacebo
Week 260.54 ± 0.521-0.47 ± 0.484
Week 390.82 ± 0.512-0.06 ± 0.478
Week 52-0.42 ± 0.578-0.33 ± 0.543
Week 650.35 ± 0.6160.07 ± 0.576
Week 780.07 ± 0.617-0.36 ± 0.598
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.1586 · Mean difference (final values): 1.01 · 95% CI -0.4 to 2.41
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.2144 · Mean difference (final values): 0.87 · 95% CI -0.51 to 2.25
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.9119 · Mean difference (final values): -0.09 · 95% CI -1.65 to 1.48
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.7339 · Mean difference (final values): 0.29 · 95% CI -1.38 to 1.95
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.6213 · Mean difference (final values): 0.43 · 95% CI -1.27 to 2.12
Other pre-specifiedChange From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT)

Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.

Time frame:
Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78.
Reported as:
Least squares mean · score on a scale
Change From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT)
score on a scalePridopidinePlacebo
Week 26-0.21 ± 0.568-0.03 ± 0.530
Week 390.06 ± 0.7800.96 ± 0.729
Week 520.47 ± 0.7660.80 ± 0.720
Week 650.92 ± 0.8471.28 ± 0.790
Week 782.19 ± 0.9541.63 ± 0.916
Statistical analysis
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.8205 · Mean difference (final values): -0.18 · 95% CI -1.71 to 1.36
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.4028 · Mean difference (final values): -0.9 · 95% CI -3.0 to 1.21
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.7577 · Mean difference (final values): -0.32 · 95% CI -2.4 to 1.75
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.7605 · Mean difference (final values): -0.35 · 95% CI -2.64 to 1.93
  • Pridopidine vs Placebo · Mixed Models Analysis · p = 0.6694 · Mean difference (final values): 0.57 · 95% CI -2.05 to 3.18

Adverse events

Collected over From Screening until 2 weeks after End of Study/End of Treatment visit (total treatment period of up to 78 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pridopidine4/250 (1.6%)34/250 (13.6%)204/250 (81.6%)
Placebo1/249 (0.4%)21/249 (8.4%)212/249 (85.1%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventPridopidinePlacebo
Acute myocardial infarctionCardiac disorders0/2503/249
Suicide attemptPsychiatric disorders3/2500/249
Suicidal ideationPsychiatric disorders2/2502/249
AnxietyPsychiatric disorders1/2502/249
FallInjury, poisoning and procedural complications0/2502/249
SyncopeNervous system disorders0/2502/249
COVID-19 pneumoniaInfections and infestations2/2500/249
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2500/249
DelusionPsychiatric disorders1/2501/249
ParanoiaPsychiatric disorders1/2501/249
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPridopidinePlacebo
COVID-19Infections and infestations59/25057/249
FallInjury, poisoning and procedural complications55/25057/249
DepressionPsychiatric disorders26/25012/249
HeadacheNervous system disorders16/25025/249
DiarrheaGastrointestinal disorders21/25022/249
AnxietyPsychiatric disorders19/25016/249
NasopharyngitisInfections and infestations19/25018/249
Urinary tract infectionInfections and infestations11/25017/249
ContusionInjury, poisoning and procedural complications12/25014/249
Back painMusculoskeletal and connective tissue disorders12/25014/249

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PridopidinePlaceboTotal
<=18 years000
Between 18 and 65 years207213420
>=65 years433679
Age, Continuous
Age, Continuous(years)PridopidinePlaceboTotal
Mean52.2 ± 11.9352.7 ± 11.3952.5 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)PridopidinePlaceboTotal
Female132127259
Male118122240
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PridopidinePlaceboTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander011
Black or African American022
White242235477
More than one race123
Unknown or Not Reported5914
Region of Enrollment
Region of Enrollment(participants)PridopidinePlaceboTotal
Canada91726
Austria5611
Netherlands14822
United States10893201
Czechia6814
Poland161531
Italy283058
United Kingdom51318
France4711
Germany374178
Spain181129
HD stage at randomization
HD stage at randomization(Participants)PridopidinePlaceboTotal
HD1102103205
HD2148146294
08

Study locations

58 sites
  • Prilenia Investigational Site (Site 061)
    Davis, California 95616, United States
  • Prilenia Investigational Site (Site 051)
    San Diego, California 92093, United States
  • Prilenia Investigational Site (Site 343)
    Englewood, Colorado 80113, United States
  • Prilenia Investigational Site (Site 333)
    Washington, District of Columbia 20057, United States
  • Prilenia Investigational Site (Site 160)
    Gainesville, Florida 32611, United States
  • Prilenia Investigational Site (Site 019)
    Tampa, Florida 33620, United States
  • Prilenia Investigational Site (Site 032)
    Atlanta, Georgia 30322, United States
  • Prilenia Investigational Site (Site 088)
    Chicago, Illinois 60611, United States
  • Prilenia Investigational Site (Site 029)
    Kansas City, Kansas 66103, United States
  • Prilenia Investigational Site (Site 083)
    Wichita, Kansas 67226, United States
  • Prilenia Investigational Site (Site 087)
    Louisville, Kentucky 40292, United States
  • Prilenia Investigational Site (Site 028)
    Baltimore, Maryland 21218, United States
  • Prilenia Investigational Site (Site 017)
    Boston, Massachusetts 02114, United States
  • Prilenia Investigational Site (Site 076)
    Boston, Massachusetts 02215, United States
  • Prilenia Investigational Site (Site 027)
    Saint Louis, Missouri 63130, United States
  • Prilenia Investigational Site (Site 037)
    Albany, New York 12208, United States
  • Prilenia Investigational Site (Site 002)
    New York, New York 10027, United States
  • Prilenia Investigational Site (Site 119)
    Durham, North Carolina 27708, United States
  • Prilenia Investigational Site (Site 089)
    Cincinnati, Ohio 45221, United States
  • Prilenia Investigational Site (Site 020)
    Columbus, Ohio 43210, United States
  • Prilenia Investigational Site (Site 006)
    Portland, Oregon 97239, United States
  • Prilenia Investigational Site (Site 018)
    Philadelphia, Pennsylvania 19104, United States
  • Prilenia Investigational Site (Site 031)
    Nashville, Tennessee 37232, United States
  • Prilenia Investigational Site (Site 199)
    Houston, Texas 77004, United States
  • Prilenia Investigational Site (Site 326)
    Richmond, Virginia 23284, United States
  • Prilenia Investigational Site (Site 096)
    Seattle, Washington 98195, United States
  • Prilenia Investigational site (Site 291)
    Innsbruck, Austria
  • Prilenia Investigational Site (Site 030)
    Calgary, Alberta AB T2N 1N4, Canada
  • Prilenia Investigational Site (Site 048)
    Vancouver, British Columbia BC V6T 1Z4, Canada
  • Prilenia Investigational Site (Site 098)
    Montréal, Quebec QC H2X 3E4, Canada
  • Prilenia Investigational Site (Site 232)
    Halifax, NS B3S 1L8, Canada
  • Prilenia Investigational Site (Site 388)
    Prague, Czechia
  • Prilenia Investigational Site (Site 385)
    Lille, France
  • Prilenia Investigational Site (Site 384)
    Marseille, France
  • Prilenia Investigational Site (Site 392)
    Paris, France
  • Prilenia Investigational Site (Site 234)
    Aachen, Germany
  • Prilenia Investigational Site (Site 379)
    Bochum, Germany
  • Prilenia Investigational Site (Site 377)
    Lübeck, Germany
  • Prilenia Investigational Site (Site 376)
    Münster, Germany
  • Prilenia Investigational site (Site 292)
    Taufkirchen, Germany
  • Prilenia Investigational Site (Site 175)
    Ulm, Germany
  • Prilenia Investigational Site (Site 249)
    Bari, Italy
  • Prilenia Investigational Site (Site 394)
    Bologna, Italy
  • Prilenia Investigational Site (Site 239)
    Milano, Italy
  • Prilenia Investigational Site (Site 393)
    Napoli, Italy
  • Prilenia Investigational Site (Site 228)
    Roma, Italy
  • Prilenia Investigational Site (Site 044)
    Leiden, Netherlands
  • Prilenia Investigational Site (Site 387)
    Maastricht, Netherlands
  • Prilenia Investigational Site (Site 386)
    Gdańsk, Poland
  • Prilenia Investigational Site (Site 244)
    Kraków, Poland
  • Prilenia Investigational Site (Site 246)
    Warsaw, Poland
  • Prilenia Investigational Site (Site 380)
    Barcelona, Spain
  • Prilenia Investigational Site (Site 381)
    Burgos, Spain
  • Prilenia Investigational Site (Site 176)
    Madrid, Spain
  • Prilenia Investigational Site (Site 382)
    Valencia, Spain
  • Prilenia Investigational Site (Site 180)
    Aberdeen, United Kingdom
  • Prilenia Investigational Site (Site 390)
    Cardiff, United Kingdom
  • Prilenia Investigational Site (Site 378)
    Newcastle, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Mar 2023, 28 months.

Results were first posted in Mar 2025, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 21, 2020
StartActual
Oct 16, 2020
Primary completionActual
Mar 14, 2023
CompletionActual
Mar 21, 2024
Results first posted
Mar 12, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04556656
Lead sponsor
Prilenia
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Oct 16, 2020
Primary completion
Mar 14, 2023
Completion
Mar 21, 2024
Results posted
Mar 12, 2025
Last update
Mar 12, 2025

Study contacts

Yael Cohen
study director · Prilenia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion